Christopher Ryder

Christopher Ryder practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Christopher Ryder's NPI, 1619396322, was assigned on April 9, 2014. Christopher Ryder graduated from Cleveland Medical College, Homeopathic in 2014. Christopher Ryder holds Florida license ME156151.

Christopher Ryder's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Christopher Ryder's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Christopher Ryder is also affiliated with University Hospitals Cleveland Medical Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Christopher Ryder to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Ryder practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology is Christopher Ryder's primary specialty in the NPI Registry, under taxonomy code 207ZH0000X. Christopher Ryder is board certified in hematopathology by the American Board of Pathology. Dmand AI has Christopher Ryder's licenses on file in 2 states: Florida and Ohio.

CMS data shows 3,077 Medicare services from Christopher Ryder across 16 procedure codes in 2024, for 510 Medicare patients. Medicare paid $71,243 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 510 Medicare patients who saw Christopher Ryder in 2024. The largest group is 65 to 74, with 279 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 3.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Christopher Ryder's median patient age at 68, with 42% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Christopher Ryder for performance year 2024, reported as part of a group. Christopher Ryder accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Christopher Ryder, published from 2018 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Apoptosis, Inflammasomes and Lymphoma, B-Cell. Christopher Ryder's most frequent co-authors are Elizabeth M. Hyjek, MD, Moritz Binder, MD, MPH and Paolo F. Caimi, MD.

CMS Open Payments shows 11 general payments to Christopher Ryder from 9 drug and device companies from 2017 to 2023. Food and beverage make up the largest share, 100% of the total. Roche Diagnostics Corporation paid the most, $87.

Christopher Ryder graduated from Cleveland Medical College, Homeopathic in 2014.

Christopher Ryder is in network with 5 carriers, including Excellus BlueCross BlueShield, United Healthcare and Alliant Health Plans. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.